The overexpression of HSP90AA1 has been observed in Alzheimer’s disease, and the use of inhibitors, geldanamycin and its analogs, has been proposed as a potential therapeutic strategy due to its role in tau stabilization and amyloid-beta aggregation, a hallmark feature of this disease [79]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.